nach oben

Erschienen in:

01.03.2016 | Original paper

Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case–control study

verfasst von: Jayeon Kim, Jennifer E. Mersereau, Nikhil Khankari, Patrick T. Bradshaw, Lauren E. McCullough, Rebecca Cleveland, Sumitra Shantakumar, Susan L. Teitelbuam, Alfred I. Neugut, Ruby T. Senie, Marilie D. Gammon

Erschienen in: Cancer Causes & Control | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite the overlap between the clinical symptoms/sequelae of polycystic ovarian syndrome (PCOS) and many known reproductive risk factors for breast cancer, the relationship between PCOS and breast cancer remains unclear, possibly because of the complex heterogeneity and challenges in diagnosing PCOS over time. We hypothesized that PCOS, specific PCOS-related symptoms/sequelae, or clusters of PCOS-related symptoms/sequelae may be differentially associated with pre- versus postmenopausal breast cancer risk.

Materials and methods

Cases were 1,508 women newly diagnosed with a first primary in situ or invasive breast, and the 1,556 population-based controls were frequency-matched by age.

Results

History of physician-diagnosed PCOS was reported by 2.2 % (n = 67), among whom oral contraceptive (OC) use, irregular menstruation, and infertility due to ovulatory dysfunction were common. Using unconditional logistic regression, adjusted odds ratios (95 % CI) for PCOS were increased for premenopausal [2.74 (1.13, 6.63)], but not postmenopausal breast cancer [0.87 (0.44, 1.71)]. We used cluster analysis to investigate whether risk among all women varied by PCOS-related symptoms/sequelae, such as reproductive irregularities, OC use, and components of insulin resistance. In the cluster analysis, odds ratios were elevated among premenopausal women who had a history of OC use and no ovulatory dysfunction [1.39 (1.03, 1.88)], compared to those with fewer number of PCOS-related symptoms/sequelae.

Conclusion

PCOS and associated PCOS-related symptoms/sequelae including OC use may play a role in the development of premenopausal breast cancer. Our findings require confirmation in studies with a larger number of premenopausal women with systematically applied diagnostic criteria for PCOS.

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25:544–551CrossRefPubMed

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749CrossRefPubMed

Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685–697CrossRefPubMed

Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R (2011) Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7:219–231CrossRefPubMed

Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR et al (2008) The metabolic syndrome. Endocr Rev 29:777–822CrossRefPubMed

Garruti G, Depalo R, Vita MG, Lorusso F, Giampetruzzi F, Damato AB et al (2009) Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod Biomed Online 19:552–563CrossRefPubMed

Gammon MD, Thompson WD (1991) Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 134:818–824PubMed

Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR (1997) Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 79:494–499CrossRefPubMed

Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L (2015) Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol 136:99–103CrossRefPubMed

10.

Brinton LA, Moghissi KS, Westhoff CL, Lamb EJ, Scoccia B (2010) Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil Steril 94:1787–1792PubMedCentralCrossRefPubMed

11.

Wild S, Pierpoint T, Jacobs H, McKeigue P (2000) Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 3:101–105CrossRef

12.

Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20:748–758PubMedCentralCrossRefPubMed

13.

Goldenberg N, Glueck C (2008) Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol 60:63–75PubMed

14.

Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727CrossRef

15.

Willett WC, Tamimi R, Hankinson SE, Hazra A, Eliassen AH, Colditz GA (2014) Chapter 18: nongenetic factors in the causation of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 211–267

16.

Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144:1–10PubMedCentralCrossRefPubMed

17.

McCullough LE, Eng SM, Bradshaw PT, Cleveland RJ, Teitelbaum SL, Neugut AI et al (2012) Fat or fit: the joint effects of physical activity, weight gain, and body size on breast cancer risk. Cancer 118:4860–4868PubMedCentralCrossRefPubMed

18.

Wright CE, Zborowski JV, Talbott EO, McHugh-Pemu K, Youk A (2004) Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. Int J Obes Relat Metab Disord 28:1026–1032CrossRefPubMed

19.

Lin AW, Lujan ME (2014) Comparison of dietary intake and physical activity between women with and without polycystic ovary syndrome: a review. Adv Nutr 5:486–496PubMedCentralCrossRefPubMed

20.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE et al (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101:48–60PubMedCentralCrossRefPubMed

21.

Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M (2014) Body composition is improved during 12 months treatment with metformin alone or combined with oral contraceptives compared to treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 99:2584–2591CrossRefPubMed

22.

Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, ElGhissassi F, WHO International Agency for Research on Cancer (2005) Carcinogenicity of combined oestrogen–progestagen contraceptives and menopausal treatment. Lancet Oncol 6:552–553CrossRefPubMed

23.

Cowan LD, Gordis L, Tonascia JA, Jones GS (1981) Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 114:209–217PubMed

24.

Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S (2009) Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 19:398–405CrossRefPubMed

25.

Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E et al (2004) Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 112:312–318CrossRefPubMed

26.

Clavel-Chapelon F (2002) Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86:723–727PubMedCentralCrossRefPubMed

27.

Clavel-Chapelon F, Gerber M (2002) Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat 72:107–115PubMedCentralCrossRefPubMed

28.

Gammon MD, Neugut AI, Santella RM, Teitelbaum SL, Britton JA, Terry MB et al (2002) The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat 74:235–254CrossRefPubMed

29.

Shantakumar S, Terry MB, Teitelbaum SL, Britton JA, Millikan RC, Moorman PG et al (2007) Reproductive factors and breast cancer risk among older women. Breast Cancer Res Treat 102:365–374CrossRefPubMed

30.

Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG et al (2007) Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 165:1187–1198CrossRefPubMed

31.

Terry MB, Zhang FF, Kabat G, Britton JA, Teitelbaum SL, Neugut AI et al (2006) Lifetime alcohol intake and breast cancer risk. Ann Epidemiol 16:230–240CrossRefPubMed

32.

Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433–2440CrossRefPubMed

33.

Eng SM, Gammon MD, Terry MB, Kushi LH, Teitelbaum SL, Britton JA et al (2005) Body size changes in relation to postmenopausal breast cancer among women on Long Island, New York. Am J Epidemiol 162:229–237CrossRefPubMed

34.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef

35.

Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T (2015) Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet 293:447–456CrossRefPubMed

36.

Shen J, Terry MB, Gammon MD, Gaudet MM, Teitelbaum SL, Eng SM et al (2005) MGMT genotype modulates the associations between cigarette smoking, dietary antioxidants and breast cancer risk. Carcinogenesis 26:2131–2137CrossRefPubMed

37.

Greenland S (1989) Modeling and variable selection in epidemiologic analysis. Am J Public Health 79:340–349PubMedCentralCrossRefPubMed

38.

Selvin S (1996) Statistical analysis of epidemiologic data. Oxford University Press, New York

39.

Shrier I, Platt RW (2008) Reducing bias through directed acyclic graphs. BMC Med Res Methodol 8:70PubMedCentralCrossRefPubMed

40.

Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume I—the analysis of case–control studies. IARC Sci Publ, Lyon, pp 5–338

41.

Rothman KJ, Greenland S, Lask TL (2012) Modern epidemiology. Williams and Wilkins, Linppincott

42.

Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD (2012) The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control 23:1193–1203PubMedCentralCrossRefPubMed

43.

Milligan G (1988) A study of standardization of variables in cluster analysis. J Classif 5:181–204CrossRef

44.

45.

Schisterman EF, Cole SR, Platt RW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20:488–495PubMedCentralCrossRefPubMed

46.

Lange T, Rasmussen M, Thygesen LC (2013) Assessing natural direct and indirect effects through multiple pathways. Am J Epidemiol 179:513–518CrossRefPubMed

47.

Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L (1995) Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 62(2):138–144CrossRefPubMed

Titel: Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case–control study
verfasst von: Jayeon Kim
Jennifer E. Mersereau
Nikhil Khankari
Patrick T. Bradshaw
Lauren E. McCullough
Rebecca Cleveland
Sumitra Shantakumar
Susan L. Teitelbuam
Alfred I. Neugut
Ruby T. Senie
Marilie D. Gammon
Publikationsdatum: 01.03.2016
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 3/2016
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-016-0716-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case–control study

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Latent class model characterization of neighborhood socioeconomic status

Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative

The effect of multiple primary rules on cancer incidence rates and trends

Exposure to maternal smoking during pregnancy and risk of childhood cancer: a study using the Danish national registers

Risk factors for Barrett’s esophagus: a scoping review

Dietary total antioxidant capacity in relation to endometrial cancer risk: a case–control study in Italy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie